

Mary Ann Anderson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4078517/publications.pdf>

Version: 2024-02-01

49
papers

4,762
citations

257357

24
h-index

214721

47
g-index

50
all docs

50
docs citations

50
times ranked

5171
citing authors

#	ARTICLE	IF	CITATIONS
1	Clonal hematopoiesis, myeloid disorders and <i>BAX</i> -mutated myelopoiesis in patients receiving venetoclax for CLL. <i>Blood</i> , 2022, 139, 1198-1207.	0.6	34
2	The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs. <i>Nature Reviews Cancer</i> , 2022, 22, 45-64.	12.8	144
3	Impact of venetoclax monotherapy on the quality of life of patients with relapsed or refractory chronic lymphocytic leukemia: results from the phase 3b VENICE II trial. <i>Leukemia and Lymphoma</i> , 2022, 63, 304-314.	0.6	8
4	Single-cell sequencing demonstrates complex resistance landscape in CLL and MCL treated with BTK and BCL2 inhibitors. <i>Blood Advances</i> , 2022, 6, 503-508.	2.5	16
5	The untold effect of the combined oral contraceptive pill on anticancer drugs. <i>Lancet Haematology</i> , 2022, 9, e10-e11.	2.2	2
6	Health-related quality of life for patients with chronic lymphocytic leukaemia – A critical outcome measure in the era of highly effective therapies. <i>British Journal of Haematology</i> , 2022, 197, 394-396.	1.2	1
7	Neuroimaging findings in immune effector cell associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy. <i>Leukemia and Lymphoma</i> , 2022, 63, 2364-2374.	0.6	6
8	Addition of rituximab in relapsed/refractory chronic lymphocytic leukemia after progression on venetoclax monotherapy. <i>EJHaem</i> , 2021, 2, 266-271.	0.4	3
9	CAR-T cell therapy: practical guide to routine laboratory monitoring. <i>Pathology</i> , 2021, 53, 408-415.	0.3	10
10	Review of Venetoclax in CLL, AML and Multiple Myeloma. <i>Journal of Personalized Medicine</i> , 2021, 11, 463.	1.1	41
11	Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited-duration therapy. <i>Blood</i> , 2021, 138, 836-846.	0.6	27
12	Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition. <i>Blood Advances</i> , 2021, 5, 4054-4058.	2.5	39
13	Immune recovery in patients with mantle cell lymphoma receiving long-term ibrutinib and venetoclax combination therapy. <i>Blood Advances</i> , 2020, 4, 4849-4859.	2.5	14
14	Tumor lysis syndrome: still the Achilles heel of venetoclax in treatment of CLL?. <i>Leukemia and Lymphoma</i> , 2020, 61, 2286-2288.	0.6	2
15	Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax. <i>Blood</i> , 2020, 135, 773-777.	0.6	115
16	Undetectable peripheral blood MRD should be the goal of venetoclax in CLL, but attainment plateaus after 24 months. <i>Blood Advances</i> , 2020, 4, 165-173.	2.5	34
17	BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax. <i>Blood</i> , 2020, 135, 2266-2270.	0.6	67
18	Promises and pitfalls of targeted agents in chronic lymphocytic leukemia. , 2020, 3, 415-444.		5

#	ARTICLE	IF	CITATIONS
19	Neutropenia analysis of venetoclax monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia: Pooled data from VENICE-I and -II Phase IIIb trials.. <i>Journal of Clinical Oncology</i> , 2020, 38, e20011-e20011.	0.8	0
20	High Clonal Complexity of Resistance Mechanisms Occurring at Progression after Single-Agent Targeted Therapy Strategies in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2020, 136, 15-16.	0.6	2
21	Dynamic molecular monitoring reveals that SWI5H3 mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma. <i>Nature Medicine</i> , 2019, 25, 119-129.	15.2	147
22	Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia. <i>Cancer Discovery</i> , 2019, 9, 342-353.	7.7	306
23	BTK Leu528Trp - a Potential Secondary Resistance Mechanism Specific for Patients with Chronic Lymphocytic Leukemia Treated with the Next Generation BTK Inhibitor Zanubrutinib. <i>Blood</i> , 2019, 134, 170-170.	0.6	33
24	Three Year Update of the Phase II ABT-199 (Venetoclax) and Ibrutinib in Mantle Cell Lymphoma (AIM) Study. <i>Blood</i> , 2019, 134, 756-756.	0.6	24
25	Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2018, 378, 1211-1223.	13.9	343
26	Venetoclax Improves Quality of Life for Patients with Elapsed/Refractory Chronic Lymphocytic Leukemia. <i>Blood</i> , 2018, 132, 4858-4858.	0.6	4
27	Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study. <i>Lancet Oncology</i> , The, 2017, 18, 230-240.	5.1	287
28	Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax. <i>Blood</i> , 2017, 129, 3362-3370.	0.6	150
29	Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 826-833.	0.8	596
30	Combination ibrutinib (Ibr) and venetoclax (Ven) for the treatment of mantle cell lymphoma (MCL): Primary endpoint assessment of the phase 2 AIM study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 7520-7520.	0.8	7
31	The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism. <i>Blood</i> , 2016, 127, 3215-3224.	0.6	242
32	Transformed Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2016, 30, 1317-1332.	0.9	8
33	Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2016, 374, 311-322.	13.9	1,532
34	Current challenges and novel treatment strategies in double hit lymphomas. <i>Therapeutic Advances in Hematology</i> , 2016, 7, 52-64.	1.1	20
35	The combination of ibrutinib and venetoclax (ABT-199) to achieve complete remissions in patients with relapsed/refractory mantle cell lymphoma: Preliminary results of the phase II AIM study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 7548-7548.	0.8	9
36	BCL2 inhibition in double hit lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 1928-1929.	0.6	1

#	ARTICLE	IF	CITATIONS
37	A Phase I Study of Venetoclax (ABT-199 / GDC-0199) Monotherapy in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma. <i>Blood</i> , 2015, 126, 254-254.	0.6	61
38	Favorable Patient Survival after Failure of Venetoclax (ABT-199/ GDC-0199) Therapy for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2015, 126, 2939-2939.	0.6	10
39	The BTK Inhibitor, Bgb-3111, Is Safe, Tolerable, and Highly Active in Patients with Relapsed/ Refractory B-Cell Malignancies: Initial Report of a Phase 1 First-in-Human Trial. <i>Blood</i> , 2015, 126, 832-832.	0.6	90
40	Targeting BCL2 for the Treatment of Lymphoid Malignancies. <i>Seminars in Hematology</i> , 2014, 51, 219-227.	1.8	130
41	Determination of Recommended Phase 2 Dose of ABT-199 (GDC-0199) Combined with Rituximab (R) in Patients with Relapsed / Refractory (R/R) Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2014, 124, 325-325.	0.6	32
42	ABT-199 (GDC-0199) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL): High complete- response rate and durable disease control.. <i>Journal of Clinical Oncology</i> , 2014, 32, 7015-7015.	0.8	42
43	Phase I study of ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL): Responses observed in diffuse large B-cell (DLBCL) and follicular lymphoma (FL) at higher cohort doses.. <i>Journal of Clinical Oncology</i> , 2014, 32, 8522-8522.	0.8	40
44	Selective Bcl-2 Inhibition With ABT-199 Is Highly Active Against Chronic Lymphocytic Leukemia (CLL) Irrespective Of TP53 Mutation Or Dysfunction. <i>Blood</i> , 2013, 122, 1304-1304.	0.6	10
45	Updated results of a phase I first-in-human study of the BCL-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL).. <i>Journal of Clinical Oncology</i> , 2013, 31, 7018-7018.	0.8	19
46	Updated results of a phase I first-in-human study of the BCL-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed/refractory non-Hodgkin lymphoma (NHL).. <i>Journal of Clinical Oncology</i> , 2013, 31, 8520-8520.	0.8	6
47	The BCL-2-Specific BH3-Mimetic ABT-199 (GDC-0199) Is Active and Well-Tolerated in Patients with Relapsed Non-Hodgkin Lymphoma: Interim Results of a Phase I Study. <i>Blood</i> , 2012, 120, 304-304.	0.6	18
48	The BCL-2-Specific BH3-Mimetic ABT-199 (GDC-0199) Is Active and Well-Tolerated in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Interim Results of a Phase I First-in-Human Study. <i>Blood</i> , 2012, 120, 3923-3923.	0.6	3
49	Persistent complement-dependent anti-AnWj in a lymphoproliferative disorder: a case study and review. <i>Immunohematology</i> , 2011, 27, 83-88.	0.2	6